MIFH
SLNO

Migdal Insurance & Financial Holdings’s Soleno Therapeutics SLNO Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-658
Closed -$5K – 683
2021
Q4 		$5K Sell
658
-510
-44% -$5.35K ﹤0.01% 647
2021
Q3 		$16K Buy
+1,168
New +$16.3K ﹤0.01% 573

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM

Migdal Insurance & Financial Holdings's SLNO Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Soleno Therapeutics (SLNO) in Q1 2022, closing a stake of 658 shares — an estimated $5K sold.

Migdal Insurance & Financial Holdings first reported a position in SLNO in Q3 2021 and held it in 2 quarters. The position peaked at $16K in Q3 2021. 41 funds tracked by Wall St. Rank hold SLNO as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Soleno Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 658 Soleno Therapeutics shares in Q1 2022, an estimated $5K.
  • Migdal Insurance & Financial Holdings first reported a position in Soleno Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Soleno Therapeutics position peaked at $16K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.